Novo Nordisk A/S
8.6.2026 14:09:08 CEST | Globenewswire | Press release
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 8 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 1 June 2026, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 3,130,000 | 913,270,696 | |
| 1 June 2026 | 210,000 | 292.91 | 61,512,149 |
| 2 June 2026 | 210,000 | 280.05 | 58,810,689 |
| 3 June 2026 | 225,000 | 276.91 | 62,305,652 |
| 4 June 2026 | 225,000 | 278.01 | 62,553,306 |
| Accumulated under the programme | 4,000,000 | 1,158,452,492 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 35,944,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 4 June 2026, Novo Nordisk has since 4 February 2026 repurchased a total 18,759,179 B shares at an average share price of DKK 264.32 per B share equal to a transaction value of DKK 4,958,452,482.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Alex Bruce +45 3444 2613 axeu@novonordisk.com | Christoffer Sho Togo Tullin +45 3079 1471 cftu@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
Company announcement No 37 / 2026
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Hebrew University of Jerusalem8.6.2026 15:21:58 CEST | Press release
First-in-the-World Gene Therapy Delivers Missing Gene Directly to Infant's Brain, Marking Historic Milestone in Precision Medicine
A.P. Møller - Mærsk A/S8.6.2026 15:04:12 CEST | Press release
Transactions in connection with share buy-back program
A.P. Møller - Mærsk A/S8.6.2026 15:04:12 CEST | Pressemeddelelse
Transaktioner i henhold til aktietilbagekøbsprogram
FDH Aero8.6.2026 15:00:00 CEST | Press release
FDH Aero Enters Next Phase of Growth Through Partnership with Bain Capital and Audax Private Equity
Analytic Partners Services Inc8.6.2026 15:00:00 CEST | Press release
The $40M Divide: New Landmark Research Reveals How a Minority of Advertisers Drive Higher ROI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom